^
Association details:
| Biomarker: | HER-2 mutation |
|---|---|
| Cancer: | Esophageal Cancer |
| Drug: | zongertinib (BI 1810631) (HER2 exon 20 mutation inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1375P - Beamion Lung 1, an ongoing phase Ia/Ib trial of the HER2 TKI, BI 1810631 in patients (pts) with advanced solid tumors with HER2 aberrations: Latest data
Published date:
10/16/2023
Excerpt:
The ongoing phase Ia/Ib trial determines the safety, MTD, PK, PD and preliminary efficacy of BI 1810631 in pts with HER2 aberration-positive solid tumors (NCT04886804)....Of 24 evaluable lung cancer patients (17 are still on Tx), 11 responded (all PRs) and 12 had SD. Two patients with other tumors (esophagus; cholangiocarcinoma) also achieved PR.
Trial ID:
